QLTY GMO U.S. Quality ETF
ETF on NYSE (US) · Actively managed · Listing
Most notable sale · Lam Research Corporation
Lam Research Corporation cut by 13%
Shares went from 761,302 to 659,259 ($242M → $199M). Now 3.8% of the portfolio. Estimated trade $30.8M.
Most notable buy · NVIDIA Corporation
New position in NVIDIA Corporation
607,934 shares worth $134M. Now 2.6% of the portfolio.
Largest holding: Microsoft Corporation, raised 11%, 795,334 shares ($403M).
| Current positions Top 10 | % of book |
|---|---|
| Microsoft Corporation MSFT $403M · +11% sh | 7.8% |
| Alphabet Inc. GOOGL $251M · +11% sh | 4.9% |
| Apple Inc. AAPL $235M · +1% sh | 4.5% |
| Johnson & Johnson JNJ $227M · +1% sh | 4.4% |
| Thermo Fisher Scientific Inc TMO $214M · +29% sh | 4.1% |
| Lam Research Corporation LRCX $199M · −13% sh | 3.8% |
| Meta Platforms, Inc. META $195M · +11% sh | 3.8% |
| Broadcom Inc. AVGO $193M · +8% sh | 3.7% |
| Amazon.com, Inc. AMZN $187M · +11% sh | 3.6% |
| Salesforce, Inc. CRM $177M · +15% sh | 3.4% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Technology | 35.0% |
| Healthcare | 23.7% |
| Communication Services | 12.5% |
| Financial Services | 8.5% |
| Consumer Defensive | 7.1% |
| Consumer Cyclical | 6.5% |
| Industrials | 4.1% |
| Unclassified | 2.7% |
| Industries | % of holdings value |
|---|---|
| Software - Application | 14.5% |
| Internet Content & Information | 9.9% |
| Semiconductors | 9.7% |
| Drug Manufacturers - General | 8.5% |
| Financial Data & Stock Exchanges | 6.6% |
| Semiconductor Equipment & Materials | 6.3% |
| Healthcare Plans | 5.5% |
| Other (16) | 36.4% |
| Unclassified | 2.7% |
| Initiations 3 | Value |
|---|---|
| NVIDIA Corporation NVDA 2.6% of portfolio | $134M |
| Philip Morris International Inc PM 1.0% of portfolio | $51.0M |
| Stryker Corporation SYK 0.9% of portfolio | $48.2M |
| Increases 31 | Change |
|---|---|
| Netflix, Inc. NFLX $76.2M → $133M | +86% |
| Thermo Fisher Scientific Inc TMO $133M → $214M | +29% |
| Microsoft Corporation MSFT $323M → $403M | +11% |
| Mastercard Incorporated MA $80.2M → $131M | +36% |
| Alphabet Inc. GOOGL $254M → $251M | +11% |
| Salesforce, Inc. CRM $114M → $177M | +15% |
| Meta Platforms, Inc. META $194M → $195M | +11% |
| Amazon.com, Inc. AMZN $176M → $187M | +11% |
| Visa Inc. V $116M → $150M | +11% |
| Broadcom Inc. AVGO $216M → $193M | +8% |
| Eli Lilly and Company LLY $113M → $131M | +10% |
| Accenture PLC $103M → $116M | +11% |
| Reductions 9 | Change |
|---|---|
| Lam Research Corporation LRCX $242M → $199M | −13% |
| U.S. Bancorp USB $111M → $95.4M | −23% |
| Merck & Company, Inc. MRK $82.4M → $83.5M | −19% |
| KLA Corporation KLAC $179M → $125M | −5% |
| Elevance Health, Inc. ELV $78.7M → $75.0M | −4% |
| Procter & Gamble Company (The) PG $106M → $104M | −3% |
| Hilton Worldwide Holdings Inc. HLT $93.7M → $88.2M | −3% |
| UnitedHealth Group Incorporated UNH $128M → $131M | −<1% |
| Abbott Laboratories ABT $103M → $133M | −<1% |
| Terminations 1 | Change |
|---|---|
| Mondelez International, Inc. MDLZ was $159K | −100% |
The other 19 increases
Moody's Corporation (+85%), Coca-Cola Company (The) (+11%), GE Aerospace (+11%), Constellation Brands, Inc. (+11%), The Cigna Group (+9%), Synopsys, Inc. (+11%), Uber Technologies, Inc. (+11%), TJX Companies, Inc. (The) (+11%), Intuitive Surgical, Inc. (+11%), Texas Instruments Incorporated (+3%), Quest Diagnostics Incorporated (+11%), Brown Forman Inc (+11%), Roper Technologies, Inc. (+11%), Tradeweb Markets Inc. (+11%), Jack Henry & Associates, Inc. (+17%), PTC Inc. (+11%), Johnson & Johnson (+1%), Apple Inc. (+1%), Aramark (+<1%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Jun 30, 2026.
Total return.
Principal investment strategies
The Fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing primarily in equities of U.S. companies that the Fund's adviser, Grantham, Mayo, Van Otterloo & Co. LLC ("GMO" or the "Adviser"), believes to be of high quality. GMO believes a high quality company generally to be a company that has an established business that will deliver a high level of return on past investments and that will use cash flows to make investments with the potential for a high return on capital or to return cash to shareholders through dividends or share buybacks. Equity securities primarily include common and preferred stocks and, to a lesser extent, other stock-related securities, such as convertible securities, depositary receipts, equity real estate investment trusts ("REITs"), income trusts, and securities of other investment companies that invest primarily in equity securities. In selecting securities for purchase and sale by the Fund, GMO uses a combination of investment methods, typically considering both (1) systematic factors, based on profitability, profit stability, leverage, and other publicly available financial information, and (2) judgmental factors, based on GMO's assessment of future profitability, capital allocation, growth opportunities, and sustainability against competitive forces. The weight that each systematic and judgmental factor is given for a particular security varies over time and GMO U.S. QUALITY ETF depends on GMO's assessment of the factor's materiality and relevance to that security. GMO also may rely on valuation methodologies, such as discounted cash flow analysis and multiples of price to earnings, revenues, book values or other fundamental metrics with the objective of buying higher quality stocks at a discount to what GMO believes to be their fundamental fair (or intrinsic) value. The Fund is not subject to any limit on the frequency with which portfolio securities may be purchased or sold, and GMO makes investment decisions for the Fund without regard to portfolio turnover rates. At times, the Fund may have substantial exposure to a single asset class, industry, sector, issuer, or companies with similar market capitalizations. The Fund may invest in securities of companies of any market capitalization. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Fund's risk relative to, any securities index or securities benchmark. As an alternative to investing directly in equities or in an attempt to obtain or adjust elements of its investment exposure, the Fund may invest in other ETFs. In addition, the Fund may lend its portfolio securities. Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in equities of quality companies (see "Name Policies"). The term "quality company" means a company that (i) is included in an independently maintained index of quality companies ("Quality Index"); (ii) has financial and business characteristics that GMO determines to be similar to those of companies included in a Quality Index; or (iii) rates in the top 50% of GMO's quality rankings for companies within the Fund's investment universe. Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds) at least 80% of its assets in companies tied economically to the United States (see "Name Policies"). The Fund also may invest in GMO U.S. Treasury Fund, a mutual fund advised by GMO, or in money market funds unaffiliated with GMO, and directly in the types of investments typically held by money market funds.
Management and Contact
- Adviser
- Grantham, Mayo, Van Otterloo & Co. LLC
- Portfolio managers
-
LLC Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund: Investment Team Senior Member (Length of Service with Fund) Title Focused Equity Thomas Hancock (since the Fund's inception in 2023) Head, Focused Equity Team, GMO.
Focused Equity Ty Cobb (since the Fund's inception in 2023) Portfolio Manager, Focused Equity Team, GMO.
Focused Equity Anthony Hene (since the Fund's inception in 2023) Portfolio Manager, Focused Equity Team, GMO.
- [email protected]
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | |
|---|---|
| Return Before Taxes | 21.12% |
| Return After Taxes on Distributions | 20.89% |
| Return After Taxes on Distributions and Sale of Fund Shares | 12.64% |
| S&P 500 Index (returns reflect no deduction for fees, expenses, or taxes) | 17.88% |
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 29, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
44 lines, 42 linked, weights sum to 99.98% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Microsoft Corp | US5949181045 | Equity | 795,334 | +77,286 | 7.79% | $ 403.465M |
| Alphabet Inc | US02079K3059 | Equity | 740,929 | +72,595 | 4.86% | $ 251.434M |
| Apple Inc | US0378331005 | Equity | 742,723 | +3,892 | 4.55% | $ 235.332M |
| Johnson & Johnson | US4781601046 | Equity | 853,823 | +9,544 | 4.38% | $ 226.989M |
| Thermo Fisher Scientific Inc | US8835561023 | Equity | 346,497 | +77,270 | 4.13% | $ 213.823M |
| Lam Research Corp | US5128073062 | Equity | 659,259 | −102,043 | 3.84% | $ 198.76M |
| Meta Platforms Inc | US30303M1027 | Equity | 340,194 | +32,788 | 3.76% | $ 194.707M |
| Broadcom Inc | US11135F1012 | Equity | 521,681 | +38,844 | 3.73% | $ 193.199M |
| Amazon.com Inc | US0231351067 | Equity | 720,044 | +70,260 | 3.61% | $ 187.046M |
| Salesforce Inc | US79466L3024 | Equity | 687,508 | +88,834 | 3.42% | $ 177.061M |
| Texas Instruments Inc | US8825081040 | Equity | 673,366 | +19,474 | 3.39% | $ 175.688M |
| Visa Inc | US92826C8394 | Equity | 395,211 | +38,643 | 2.90% | $ 149.931M |
| NVIDIA Corp | US67066G1040 | Equity | 607,934 | new +607,934 | 2.59% | $ 134.22M |
| Netflix Inc | US64110L1061 | Equity | 1,645,087 | +759,422 | 2.58% | $ 133.334M |
| Abbott Laboratories | US0028241000 | Equity | 1,203,746 | −840 | 2.57% | $ 132.845M |
| Eli Lilly & Co | US5324571083 | Equity | 113,212 | +10,539 | 2.53% | $ 130.956M |
| UnitedHealth Group Inc | US91324P1021 | Equity | 335,913 | −1,206 | 2.53% | $ 130.808M |
| Mastercard Inc | US57636Q1040 | Equity | 221,478 | +59,058 | 2.52% | $ 130.519M |
| KLA Corp | US4824801009 | Equity | 711,352 | +618,127 | 2.41% | $ 124.807M |
| Aramark | US03852U1060 | Equity | 2,103,281 | +6,709 | 2.29% | $ 118.436M |
|
Accenture PLC
|
IE00B4BNMY34 | Equity | 610,861 | +59,721 | 2.24% | $ 115.917M |
| Procter & Gamble Co/The | US7427181091 | Equity | 717,305 | −19,278 | 2.01% | $ 104.095M |
| Coca-Cola Co/The | US1912161007 | Equity | 1,114,845 | +108,896 | 1.91% | $ 98.853M |
| US Bancorp | US9029733048 | Equity | 1,549,965 | −467,493 | 1.84% | $ 95.447M |
| General Electric Co | US3696043013 | Equity | 275,698 | +26,933 | 1.79% | $ 92.555M |
| Hilton Worldwide Holdings Inc | US43300A2033 | Equity | 278,794 | −7,222 | 1.70% | $ 88.177M |
| Merck & Co Inc | US58933Y1055 | Equity | 565,435 | −129,031 | 1.61% | $ 83.549M |
| Cigna Group/The | US1255231003 | Equity | 284,704 | +24,604 | 1.52% | $ 78.601M |
| Elevance Health Inc | US0367521038 | Equity | 191,162 | −8,903 | 1.45% | $ 75.039M |
| Constellation Brands Inc | US21036P1084 | Equity | 552,037 | +53,866 | 1.39% | $ 72.107M |
| Synopsys Inc | US8716071076 | Equity | 155,916 | +15,223 | 1.32% | $ 68.539M |
| Uber Technologies Inc | US90353T1007 | Equity | 867,530 | +84,312 | 1.27% | $ 65.629M |
| TJX Cos Inc/The | US8725401090 | Equity | 469,066 | +45,669 | 1.21% | $ 62.813M |
| Intuitive Surgical Inc | US46120E6023 | Equity | 145,697 | +14,052 | 1.06% | $ 54.907M |
| Quest Diagnostics Inc | US74834L1008 | Equity | 217,286 | +21,078 | 1.01% | $ 52.214M |
| Philip Morris International Inc | US7181721090 | Equity | 272,522 | new +272,522 | 0.99% | $ 51.043M |
| Stryker Corp | US8636671013 | Equity | 148,998 | new +148,998 | 0.93% | $ 48.246M |
| Brown-Forman Corp | US1156372096 | Equity | 1,542,742 | +149,888 | 0.79% | $ 40.991M |
| Roper Technologies Inc | US7766961061 | Equity | 95,046 | +9,368 | 0.78% | $ 40.36M |
| Tradeweb Markets Inc | US8926721064 | Equity | 359,473 | +35,130 | 0.75% | $ 38.715M |
| PTC Inc | US69370C1009 | Equity | 230,117 | +22,249 | 0.69% | $ 35.838M |
| Jack Henry & Associates Inc | US4262811015 | Equity | 142,010 | +21,123 | 0.46% | $ 23.845M |
| Moody's Corp | US6153691059 | Equity | 45,963 | +21,165 | 0.45% | $ 23.195M |
|
State Street Global Advisors
|
US8574928706 | Money market | 21,955,042.24 | +9,104,307.06 | 0.42% | $ 21.955M |
Trades May 31, 2026 to Aug 31, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| NVIDIA Corp | New | — | 607,934 | +607,934 | $ 134.22M | |
| KLA Corp | Bought | 93,225 | 711,352 | +618,127 | $ 108.45M | |
| Netflix Inc | Bought | 885,665 | 1,645,087 | +759,422 | $ 61.551M | |
| Philip Morris International Inc | New | — | 272,522 | +272,522 | $ 51.043M | |
| Stryker Corp | New | — | 148,998 | +148,998 | $ 48.246M | |
| Thermo Fisher Scientific Inc | Bought | 269,227 | 346,497 | +77,270 | $ 47.683M | |
| Microsoft Corp | Bought | 718,048 | 795,334 | +77,286 | $ 39.206M | |
| Mastercard Inc | Bought | 162,420 | 221,478 | +59,058 | $ 34.803M | |
| Lam Research Corp | Sold | 761,302 | 659,259 | −102,043 | $ -30.765M | |
| US Bancorp | Sold | 2,017,458 | 1,549,965 | −467,493 | $ -28.788M | |
| Alphabet Inc | Bought | 668,334 | 740,929 | +72,595 | $ 24.635M | |
| Salesforce Inc | Bought | 598,674 | 687,508 | +88,834 | $ 22.878M | |
| Merck & Co Inc | Sold | 694,466 | 565,435 | −129,031 | $ -19.066M | |
| Meta Platforms Inc | Bought | 307,406 | 340,194 | +32,788 | $ 18.766M | |
| Amazon.com Inc | Bought | 649,784 | 720,044 | +70,260 | $ 18.251M | |
| Visa Inc | Bought | 356,568 | 395,211 | +38,643 | $ 14.66M | |
| Broadcom Inc | Bought | 482,837 | 521,681 | +38,844 | $ 14.385M | |
| Eli Lilly & Co | Bought | 102,673 | 113,212 | +10,539 | $ 12.191M | |
|
Accenture PLC
|
Bought | 551,140 | 610,861 | +59,721 | $ 11.333M | |
| Moody's Corp | Bought | 24,798 | 45,963 | +21,165 | $ 10.681M | |
| Coca-Cola Co/The | Bought | 1,005,949 | 1,114,845 | +108,896 | $ 9.656M | |
| General Electric Co | Bought | 248,765 | 275,698 | +26,933 | $ 9.042M | |
| Constellation Brands Inc | Bought | 498,171 | 552,037 | +53,866 | $ 7.036M | |
| Cigna Group/The | Bought | 260,100 | 284,704 | +24,604 | $ 6.793M | |
| Synopsys Inc | Bought | 140,693 | 155,916 | +15,223 | $ 6.692M | |
| Uber Technologies Inc | Bought | 783,218 | 867,530 | +84,312 | $ 6.378M | |
| TJX Cos Inc/The | Bought | 423,397 | 469,066 | +45,669 | $ 6.116M | |
| Intuitive Surgical Inc | Bought | 131,645 | 145,697 | +14,052 | $ 5.296M | |
| Texas Instruments Inc | Bought | 653,892 | 673,366 | +19,474 | $ 5.081M | |
| Quest Diagnostics Inc | Bought | 196,208 | 217,286 | +21,078 | $ 5.065M | |
| Brown-Forman Corp | Bought | 1,392,854 | 1,542,742 | +149,888 | $ 3.983M | |
| Roper Technologies Inc | Bought | 85,678 | 95,046 | +9,368 | $ 3.978M | |
| Tradeweb Markets Inc | Bought | 324,343 | 359,473 | +35,130 | $ 3.784M | |
| Jack Henry & Associates Inc | Bought | 120,887 | 142,010 | +21,123 | $ 3.547M | |
| Elevance Health Inc | Sold | 200,065 | 191,162 | −8,903 | $ -3.495M | |
| PTC Inc | Bought | 207,868 | 230,117 | +22,249 | $ 3.465M | |
| Procter & Gamble Co/The | Sold | 736,583 | 717,305 | −19,278 | $ -2.798M | |
| Johnson & Johnson | Bought | 844,279 | 853,823 | +9,544 | $ 2.537M | |
| Hilton Worldwide Holdings Inc | Sold | 286,016 | 278,794 | −7,222 | $ -2.284M | |
| Apple Inc | Bought | 738,831 | 742,723 | +3,892 | $ 1.233M | |
| UnitedHealth Group Inc | Sold | 337,119 | 335,913 | −1,206 | $ -469.628K | |
| Aramark | Bought | 2,096,572 | 2,103,281 | +6,709 | $ 377.784K | |
| Mondelez International Inc | Closed | 2,592 | — | −2,592 | $ -158.553K | |
| Abbott Laboratories | Sold | 1,204,586 | 1,203,746 | −840 | $ -92.702K |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up